Hikma Licenses Rights To Theravance’s Vibativ For MENA Expansion
This article was originally published in PharmAsia News
Executive Summary
Hikma Pharmaceuticals in-licensed Middle East and North Africa rights for Theravance’s injectable antibiotic Vibativ for Gram-positive bacterial infections to build on the Jordan firm’s plans for MENA expansion.